Business Context and Reporting Period
Company: OrthoPediatrics Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: August 10, 2022
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Common Stock Offering: 750,000 shares at $55.00 per share.
- Pre-Funded Warrants: Warrants to purchase up to 1,525,000 shares sold to Squadron Capital LLC (the Company's largest investor) at a price of $54.99975 per warrant ($55.00 minus $0.00025 exercise price).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 341,250 additional shares.
- Estimated Net Proceeds: Approximately $121.0 million, or approximately $139.2 million if the over-allotment option is exercised in full.
- Expected Closing Date: On or about August 15, 2022.
Note: The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes and Transaction Structure
The primary material change is the execution of the Underwriting Agreement with Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated. Key structural elements include:
- Investor Participation: Squadron Capital LLC is purchasing the pre-funded warrants. These warrants have an exercise price of $0.00025 per share but are subject to Hart-Scott-Rodino (HSR) Act waiting periods before they can be exercised. Once exercisable, Squadron is obligated to exercise them within five business days.
- Lock-Up Agreement: The Company, its officers, directors, and Squadron have agreed not to sell or dispose of any Common Stock or convertible securities for 90 days following the date of the Underwriting Agreement, subject to certain exceptions and underwriter consent.
Guidance, Outlook, and Risks
Outlook: The Company expects the offering to close on or about August 15, 2022, subject to customary closing conditions. The proceeds are intended to support the Company's operations, though specific allocation details are not provided in this text.
Risks and Contingencies:
- Forward-Looking Statements: The filing contains forward-looking statements regarding the timing and completion of the offering and expected net proceeds. Actual results may differ materially due to risks detailed in the Company's Form 10-K and the Preliminary Prospectus Supplement.
- Regulatory Approval: The exercise of the pre-funded warrants by Squadron Capital is contingent upon the expiration of HSR Act waiting periods or an exemption from notification requirements.
Investor Verification Checklist
- Verify the final closing date of the offering (expected August 15, 2022) and confirm if the over-allotment option was exercised.
- Review the Preliminary Prospectus Supplement and accompanying prospectus for detailed risk factors and use of proceeds.
- Monitor the status of the HSR Act waiting periods to determine when Squadron Capital LLC will be obligated to exercise the pre-funded warrants.
- Confirm the final net proceeds received after deducting underwriting discounts, commissions, and offering expenses.